文献速递糖尿病

精氨酸酶抑制改善2型糖尿病患者的微血管内皮功能

Arginase Inhibition Improves Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2016-07-11

这项前瞻性干预研究在12例2型糖尿病伴微血管功能障碍患者和12名年龄匹配健康对照中,用激光多普勒血流仪评估离子电渗给予乙酰胆碱和硝普钠前后的微血管内皮依赖性和非依赖性舒张。给予精氨酸酶抑制剂Nω-羟基-去甲-L-精氨酸后,糖尿病患者微血管内皮功能显著改善至健康对照水平,内皮非依赖性舒张无显著变化。糖尿病患者鸟氨酸水平及鸟氨酸/瓜氨酸、鸟氨酸/精氨酸比值较高(P < .05),提示精氨酸酶活性增加。

要点

  • 2型糖尿病患者微血管内皮依赖性舒张受损(P < .05)。
  • 给予精氨酸酶抑制剂后,糖尿病患者微血管内皮功能显著改善至健康对照水平。
  • 糖尿病患者鸟氨酸水平及鸟氨酸/瓜氨酸、鸟氨酸/精氨酸比值较高(P < .05)。

核心结论

  • 精氨酸酶抑制改善2型糖尿病伴微血管功能障碍患者的微血管内皮功能。
  • 精氨酸酶抑制可能代表改善2型糖尿病患者微血管内皮功能的新治疗策略。

研究设计与样本

  • 前瞻性干预研究,纳入2型糖尿病患者12例和年龄匹配健康对照12名。
  • 用激光多普勒血流仪在离子电渗给予乙酰胆碱和硝普钠时测定微血管内皮依赖性和非依赖性舒张,并于给予精氨酸酶抑制剂Nω-羟基-去甲-L-精氨酸前及后120分钟测定。
  • 测定参与精氨酸酶和一氧化氮合酶活性的血浆氨基酸比值,激光多普勒血流仪数据为主要结局变量。

主要发现

  • 2型糖尿病受试者微血管内皮依赖性舒张受损(P < .05)。
  • 给予Nω-羟基-去甲-L-精氨酸后,2型糖尿病患者微血管内皮功能显著改善至健康对照水平。
  • 内皮非依赖性血管舒张无显著变化。
  • 2型糖尿病受试者鸟氨酸水平及鸟氨酸/瓜氨酸、鸟氨酸/精氨酸比值较高(P < .05),提示精氨酸酶活性增加。

临床怎么用

  • 作者认为精氨酸酶抑制可能代表改善2型糖尿病患者微血管内皮功能的新治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The development of microvascular complications in diabetes is a complex process in which endothelial dysfunction is important. Emerging evidence suggests that arginase is a key mediator of endothelial dysfunction in type 2 diabetes mellitus by reciprocally regulating nitric oxide bioavailability. The aim of this prospective intervention study was to test the hypothesis that arginase activity is increased and that arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. DESIGN: Microvascular endothelium-dependent and -independent dilatation was determined in patients with type 2 diabetes (n = 12) and healthy age-matched control subjects (n = 12) with laser Doppler flowmetry during iontophoretic application of acetylcholine and sodium nitroprusside, respectively, before and after administration of the arginase inhibitor Nω-hydroxy-nor-L-arginine (120 min). Plasma ratios of amino acids involved in arginase and nitric oxide synthase activities were determined. The laser Doppler flowmetry data were the primary outcome variable. RESULTS: Microvascular endothelium-dependent dilatation was impaired in subjects with type 2 diabetes (P < .05). After administration of Nω-hydroxy-nor-L-arginine, microvascular endothelial function improved significantly in patients with type 2 diabetes to the level observed in healthy controls. Endothelium-independent vasodilatation did not change significantly. Subjects with type 2 diabetes had higher levels of ornithine and higher ratios of ornithine/citrulline and ornithine/arginine (P < .05), suggesting increased arginase activity. CONCLUSION: Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. Arginase inhibition may represent a novel therapeutic strategy to improve microvascular endothelial function in patients with type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kövamees O, Shemyakin A, Checa A, et al. Arginase Inhibition Improves Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016. PMID: 27399350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。